ResearchMoz

Asthma Therapeutics Market to 2019 - Breakthrough Biologics to Enhance Treatment of Severe Asthma and Drive Market Growth

GBI Research
Published Date » 2013-10-09
No. Of Pages » N/A
   
 GBI Research, a leading business intelligence provider, has released its latest research report “Asthma Market to 2019”. The asthma market is forecast to grow marginally over the forecast period across the leading eight developed nations, from $16.6 billion in 2012 to a projected value of $21.6 billion in 2019. This growth is expected despite the generic erosion facing the leading brands, and is a consequence of new market entrants and a disease prevalence that continues to rise, albeit not at rates as high as have been seen in the past. Some new, costly asthma therapies could be set to enter the asthma market, including GlaxoSmithKline’s (GSK’s) recently approved Relvar (fluticasone/vilanterol), and multiple monoclonal antibodies (mAbs). ...
Table of Content

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Disease Introduction
2.2 Symptoms
2.3 Etiology
2.4 Pathophysiology
2.5 Diagnosis
2.6 Assessment of Disease Severity
2.7 Treatment
2.8 Treatment Algorithm

3 Marketed Products
3.1 Product Profiles
3.1.1 Advair Diskus (fluticasone and salmeterol) – GlaxoSmithKline
3.1.2 Symbicort (budesonide/formoterol) – AstraZeneca, Co-promotion with Astellas Pharma Inc
3.1.3 Singulair (montelukast) – Merck & Co
3.1.4 Xolair (omalizumab) – Novartis and Genentech
3.1.5 Foradil (formoterol) – Novartis (Co-marketed by Novartis and Schering Corporation)
3.1.6 Dulera/Zenhale (mometasone/formoterol) – Merck & Co
3.1.7 Relvar/Breo – GlaxoSmithKline/Theravance

4 Asthma Pipeline
4.1 Overview
4.2 Mechanisms of Action in the Pipeline
4.3 Clinical Trials
4.3.1 Failure Rate
4.3.2 Clinical Trial Duration
4.3.3 Clinical Trial Size
4.3.4 Comparative Clinical Trial Metrics Analysis
4.4 Promising Pipeline Molecules
4.4.1 Reslizumab – Teva Pharmaceutical ltd
4.4.2 Mepolizumab - GlaxoSmithKline
4.4.3 Lebrikizumab – Roche/Genentech
4.4.4 Veramyst - GlaxoSmithKline
4.4.5 Andolast – Rottapharm Madaus
4.4.6 Spiriva (Tiotropium Bromide) – Boehringer Ingelheim
4.5 Heat Map of Safety and Efficacy for Pipeline and Marketed Products

5 Market Forecast to 2019
5.1 Geographical Markets
5.1.1 Global Market
5.1.2 North America
5.1.3 Top Five Countries of Europe
5.1.4 Japan
5.2 Drivers and Barriers for the Asthma Therapeutics Market
5.2.1 Drivers
5.2.2 Barriers

6 Strategic Consolidations
6.1 Major Licensing Deals
6.2 Major Co-development Deals

7 Appendix
7.1 All Pipeline Drugs by Phase
7.1.1 Discovery
7.1.2 Preclinical
7.1.3 Phase I
7.1.4 Phase II
7.1.5 Phase III
7.1.6 Filed
7.1.7 Undisclosed
7.2 Market Forecast to 2019
7.2.1 Global
7.2.2 US
7.2.3 Canada
7.2.4 UK
7.2.5 France
7.2.6 Germany
7.2.7 Italy
7.2.8 Spain
7.2.9 Japan
7.3 References
7.3.1 References for Pipeline Heat Map
7.3.2 References for Marketed Heat Map
7.4 Market Definitions
7.5 Abbreviations
7.6 Methodology
7.7 Coverage
7.8 Secondary Research
7.9 Therapeutic Landscape
7.10 Epidemiology-Based Forecasting
7.10.1 Analogous Forecasting Methodology
7.11 Market Size by Geography
7.11.1 Forecasting Model for Therapeutic Areas
7.12 Geographical Landscape
7.13 Pipeline Analysis
7.14 Competitive Landscape
7.14.1 Expert Panel Validation
7.15 Contact Us
7.16 Disclaimer

List of Tables


Table 1: Asthma Therapeutics Market, Global, Classification of Asthma Severity in Children of 0–4 Years of Age
Table 2: Asthma Therapeutics Market, Global, Classification of Asthma Severity in Children of 5–11 Years of Age
Table 3: Asthma Therapeutics Market, Global, Classification of Asthma Severity in Youths = 12 Years of Age and Adults
Table 4: Management of Chronic Asthma
Table 5: Management of Acute Asthma
Table 6: Asthma Therapeutics Market, Global, Pipeline, Discovery, 2013
Table 7: Asthma Therapeutics Market, Global, Pipeline, Preclinical, 2013
Table 8: Asthma Therapeutics Market, Global, Pipeline, Phase I, 2013
Table 9: Asthma Therapeutics Market, Global, Pipeline, Phase II, 2013
Table 10: Asthma Therapeutics Market, Global, Pipeline, Phase III, 2013
Table 11: Asthma Therapeutics Market, Global, Pipeline, Filed, 2013
Table 12: Asthma Therapeutics Market, Global, Pipeline, Undisclosed, 2013
Table 13: Asthma, Global, Market Forecast, 2012–2019
Table 14: Asthma, US, Market Forecast, 2012–2019
Table 15: Asthma, Canada, Market Forecast, 2012–2019
Table 16: Asthma, UK, Market Forecast, 2012–2019
Table 17: Asthma, France, Market Forecast, 2012–2019
Table 18: Asthma, Germany, Market Forecast, 2012–2019
Table 19: Asthma, Italy, Market Forecast, 2012–2019
Table 20: Asthma, Spain, Market Forecast, 2012–2019
Table 21: Asthma, Japan, Market Forecast, 2012–2019

List of Figures


Figure 1: Asthma Therapeutics Market, Global, Pipeline, 2013
Figure 2: Asthma Therapeutics Market, Global, Pipeline by Mechanism of Action, 2013
Figure 3: Asthma Therapeutics Market, Global, Pipeline by Mechanism of Action, Phase I, 2013
Figure 4: Asthma Therapeutics Market, Global, Pipeline by Mechanism of Action, Phase II, 2013
Figure 5: Asthma Therapeutics Market, Global, Pipeline by Mechanism of Action, Phase III, 2013
Figure 6: Asthma Therapeutics Market, Global, Clinical Trial Failure Rate, 2013
Figure 7: Asthma Therapeutics Market, Global, Clinical Trial Failure Rates by Mechanism of Action, Phase I, 2013
Figure 8: Asthma Therapeutics Market, Global, Clinical Trial Failure Rates by Mechanism of Action, Phase II, 2013
Figure 9: Asthma Therapeutics Market, Global, Clinical Trial Failure Rates by Mechanism of Action, Phase III, 2013
Figure 10: Asthma Therapeutics Market, Global, Pipeline, Clinical Trial Duration, 2013
Figure 11: Asthma Therapeutics Market, Global, Pipeline, Clinical Trial Duration by Mechanism, Phase I, 2013
Figure 12: Asthma Therapeutics Market, Global, Pipeline, Clinical Trial Duration by Mechanism, Phase II, 2013
Figure 13: Asthma Therapeutics Market, Global, Pipeline, Clinical Trial Duration by Mechanism, Phase III, 2013
Figure 14: Asthma Therapeutics Market, Global, Pipeline, Clinical Trial Size, 2013
Figure 15: Asthma Therapeutics Market, Global, Pipeline, Clinical Trial Size by Mechanism, Phase I, 2013
Figure 16: Asthma Therapeutics Market, Global, Pipeline, Clinical Trial Size by Mechanism, Phase II, 2013
Figure 17: Asthma Therapeutics Market, Global, Pipeline, Clinical Trial Size by Mechanism, Phase III, 2013
Figure 18: Asthma Therapeutics Market, Global, Pipeline, Mechanism of Action Heat Map, 2012
Figure 19: Asthma Therapeutics Market, Global, Reslizumab Forecast ($m), 2014–2019
Figure 20: Asthma Therapeutics Market, Global, Mepolizumab Forecast ($m), 2015–2019
Figure 21: Asthma Therapeutics Market, Global, Lebrikizumab Forecast ($m), 2015–2019
Figure 22: Asthma Therapeutics Market, Global, Veramyst Forecast ($m), 2014–2019
Figure 23: Asthma Therapeutics Market, Global, Andolast Forecast ($m), 2015–2019
Figure 24: Asthma Therapeutics Market, Global, Tiotropium Bromide Forecast ($m), 2014–2019
Figure 25: Asthma Therapeutics Market, Global, Pipeline, Efficacy Heat Map, 2013
Figure 26: Asthma Therapeutics Market, Global, Pipeline, Safety Heat Map, 2013
Figure 27: Asthma Therapeutics Market, Global, Marketed Products, Safety and Efficacy Heat Map, 2013
Figure 28: Asthma Therapeutics Market, Global, Pipeline, Competitor Grid, 2013
Figure 29: Asthma Therapeutics Market, Global, Treatment Patterns, 2012–2019
Figure 30: Asthma Therapeutics Market, Global, Market Size, 2012–2019
Figure 31: Asthma Therapeutics Market, North America, Treatment Patterns, 2012–2019
Figure 32: Asthma Therapeutics Market, North America, Annual Cost of Treatment, 2012–2019
Figure 33: Asthma Therapeutics Market, North America, Market Size, 2012–2019
Figure 34: Asthma Therapeutics Market, Top Five EU Countries, Treatment Patterns, 2012–2019
Figure 35: Asthma Therapeutics Market, Top Five EU Countries, Annual Cost of Treatment, 2012–2019
Figure 36: Asthma Therapeutics Market, Top Five EU Countries, Market Size ($bn), 2012–2019
Figure 37: Asthma Therapeutics Market, Japan, Treatment Patterns and Annual Cost of Treatment, 2012–2019
Figure 38: Asthma Therapeutics Market, Japan, Market Size, 2012–2019
Figure 39: Asthma Therapeutics Market, Global, Major Licensing Deals, 2006–2013
Figure 40: Asthma Therapeutics Market, Global, Major Licensing Deals, 2006–2013
Figure 41: Asthma Therapeutics Market, Global, Major Licensing Deals, 2006–2013
Figure 42: Asthma Therapeutics Market, Global, Major Licensing Deals, Completed and Terminated
Figure 43: Asthma Therapeutics Market, Global, Major Licensing Deals by Phase and Molecule Type, 2006–2012
Figure 44: Asthma Therapeutics Market, Global, Major Licensing Deals, Mechanism of Action
Figure 45: Asthma Therapeutics Market, Global, Major Co-developments by Region and Value, 2006–2013
Figure 46: Asthma Therapeutics Market, Global, Major Co-developments by Year, 2006–2013
Figure 47: Asthma Therapeutics Market, Global, Major Co-developments by Phase, 2006–2013
Figure 48: Asthma Therapeutics Market, Global, Major Co-developments by Phase and Molecule Type, 2006–2013
Figure 49: Forecasting Model for Therapeutic Areas

Upcoming Reports:

Salad Dressings and Mayonnaise Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
By - Transparency Market Research
Salad dressing refers to garnishing of salads by adding condiment such as sauces, cream, nuts and cheese to enhance their taste and experience. Mayonnaise is a thick creamy sauce which is made from egg yolk, oil, vinegar and lemon juice. It is used as a condiment or spread in sandwiches and often accompany salads to impart taste and creamy delight in them. In this report, Salad dressing and mayonnaise market is segmented in six different categories such as liquid salad dressing, creamy salad toppings, potato salad toppings, mayonnaise (all varieties), reduced/low-calorie salad dressing and...
Automotive Sealants Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020
By - Transparency Market Research
A sealant is a viscous material which penetrates by capillary action into a substrate where it is applied and provides a barrier to air, dust, liquids and others, from passing from one substrate to another. Sealants are corrosion resistant, insoluble in most media and have adhesion. The adhesion of sealants is slightly lower compared to adhesives. Sealants lie between high strength adhesives and low strength caulks and putties. However, they have higher elongation compared to adhesives. There are numerous types of sealants which are used across various industries such as building &...
Sorbates Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020
By - Transparency Market Research
Sorbates are salts and esters that are manufactured using sorbic acid. Sorbates are categorized as calcium sorbate, potassium sorbate and sodium sorbate. Calcium sorbate is the calcium salt of sorbic acid. Sodium sorbate is the sodium salt of sorbic acid. Sodium sorbate is a food additive which is having the E-number E201. Potassium sorbate is one of the most widely used sub category of sorbate. Potassium sorbate is industrially produced by neutralizing sorbic acid with potassium hydroxide. Sorbic acid which is an essential raw material to manufacture sorbate occurs naturally in some...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

A Health Tech Incubator Started by GE Healthcare
Oct 30, 2014  
For the very first time, a health tech start up campus has been established by GE Healthcare at its headquarters at Helsinki, Finland. This area already has about twenty such healthcare start ups that are working on cloud services, wireless technologies, apps, and sensors that aim at improving healthcare. The main rationale behind such a step is providing opportunities for further...
Net Earnings of DuPont Increases 52% despite Agricultural Turmoil
Oct 29, 2014  
DuPont - The Wilmington, Del-based leading chemical company faced decline of three percent sales to $7.5 billion in the quarter ending of September 30. The company’s third-quarter earnings were increased by 52 percent to $433 million albeit the slow global growth and agricultural downside.   The company witnessed the biggest drags from chemical sales with eight percent...
Appeal for Sanitization in Construction Industry through Government Regulations: CIOB Ghana
Oct 29, 2014  
Rockson Dogbegah - The Chairman of the Chartered Institute of Building Ghana commented that the construction industry needs a thorough cleaning up and assurance of proper growth. Mr. Dogbegah also said that a few factors are extremely important for a proper development in the construction industry. These include keen adherence to standards, supreme sense of professionalism, and sheer pursuance...
Facebook Hints of Rise in Expenses in 2015, Shares Drop
Oct 29, 2014  
Facebook has announced on Tuesday that it is prepping for a dramatic rise in spending in the year 2015. This warning has come combined with a projected slowdown in the company’s revenues after revenues were analyzed at the end of the third quarter of the year. The plans of such hefty spending in the next financial year by the company are indicative of stress in the investor...
Samsung Records Poorest Profits in Q3 2014
Oct 29, 2014  
In the quarter ending September 2014, Samsung Electronics Co. Ltd registered the smallest earnings ever in two years. The drop in earnings can be easily attributed to heavy competition from new Chinese devices and the Apple phones. The net income stood at US$4 billion for the South Korea-based company. Apple has been Samsung’s strongest contender ever since the latter entered the...